CONTE, Pierfranco

CONTE, Pierfranco  

Mostra records
Risultati 1 - 20 di 378 (tempo di esecuzione: 0.026 secondi).
Titolo Data di pubblicazione Autore(i) File
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 1-gen-2017 Conte, P; Bisagni, G; Frassoldati, A; Brandes, A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Musolino, A; Garrone, O; Donadio, M; Cavazzini, G; Turletti, A; Zamagni, C; Danese, S; Ferro, A; Piacentini, F; Balduzzi, S; D'Amico, R; Guarneri, V
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 1-gen-2010 Barbieri, E.; Bettelli, S.; Piacentini, F.; Ficarra, G.; Conte, Pf.; Guarneri, V.
4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study. 1-gen-1987 M., Bruzzone; S., Chiara; A., Falcone; G., Graziani; Conte, Pierfranco; R., Rosso
41. HER2+ EARLY BREAST CANCER: DO WE HAVE ALL THE NECESSARY ANSWERS? 1-gen-2012 Conte, P.; Verrusio, Manuela; Piacentini, F.
5-fluorouracil administered as a 48-hour semi-intermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients 1-gen-2004 Allegrini, G; Falcone, A; DI MARSICO, R; Lencioni, M; Masi, G; Galli, C; Cupini, S; Pfanner, E; Marcucci, L; Conte, Pierfranco
5-Fluoruracil administered as a 48-hours chronomodulated infusion in combination with Leucovorin and Cisplatin: a randomized phase II study in metastatic colorectal cancer. 1-gen-2001 A., Falcone; G., Allegrini; G. L., Masi; M., Lencioni; E., Pfanner; I., Brunetti; R., Danesi; G., Bocci; M., Del Tacca; Conte, Pierfranco
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 1-gen-2018 Conte, P; Frassoldati, A; Bisagni, G; Brandes, Aa; Donadio, M; Garrone, O; Piacentini, F; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Molino, A; Musolino, A; Ferro, A; Maltoni, R; Danese, S; Zamagni, C; Rimanti, A; Cagossi, K; Russo, A; Pronzato, P; Giovanardi, F; Moretti, G; Lombardo, L; Schirone, A; Beano, A; Amaducci, L; Bajardi, Ea; Vicini, R; Balduzzi, Sara; D'Amico, R; Guarneri, Valentina
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 1-gen-2010 Guarneri, Valentina; Frassoldati, A; Gebbia, V; Bisagni, G; Cavanna, L; Donadio, M; Lelli, G; Musolino, A; Colucci, G; Banna, Gl; Degli Esposti, R; Ferro, A; Grasso, F; Zamagni, C; Amadori, D; Aieta, M; Molino, A; Garrone, O; Aitini, E; Fornari, G; Cascinu, Stefano; Rossi, G; D'Amico, Roberto; Conte, Pierfranco
[Experimentation with Di Bella polychemotherapy in Tuscany]. 1-gen-2000 C., Orlandini; G., Amunni; Conte, Pierfranco; G., Francini; G. C., Rossini; D., Vanni; G. d., Riferimento
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 1-gen-2017 Gelsomino, Fabio; Bertolini, Federica; Luppi, Gabriele; Spallanzani, Andrea; Pettorelli, Elisa; Reggiani Bonetti, Luca; Meduri, Bruno; Manco, Gianrocco; Conte, Pierfranco; Cascinu, Stefano
A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer. 1-gen-1996 Conte, Pierfranco; A., Michelotti; E., Baldini; B., Salvadori; A., Gennari; M. D., Prato; C., Tibaldi; E., Salzano; A., Gentile
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. 1-gen-1997 A., Michelotti; B., Salvadori; S., Donati; A., Tognoni; C., Tibaldi; Conte, Pierfranco
A Long-Acting Depot Lanreotide in the treatment of patients with Advanced Neuroendocrine Tumors. 1-gen-2000 S., Ricci; A., Antonuzzo; L., Galli; C., Orlandini; M., Ferdeghini; C., Boni; M., Roncella; F., Mosca; Conte, Pierfranco
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 1-gen-2020 Prat, A; Guarneri, V; Paré, L; Griguolo, G; Pascual, T; Dieci, Mv; Chic, N; González-Farré, B; Frassoldati, A; Sanfeliu, E; Cejalvo, Jm; Muñoz, M; Bisagni, G; Brasó-Maristany, F; Urso, L; Vidal, M; Brandes, Aa; Adamo, B; Musolino, A; Miglietta, F; Conte, B; Oliveira, M; Saura, C; Pernas, S; Alarcón, J; Llombart-Cussac, A; Cortés, J; Manso, L; López, R; Ciruelos, E; Schettini, F; Villagrasa, P; Carey, La; Perou, Cm; Piacentini, F; D'Amico, R; Tagliafico, E; Parker, Js; Conte, P
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 1-gen-2015 Prapa, Malvina; Caldrer, Sara; Spano, Maria Carlotta; Bestagno, Marco; Golinelli, Giulia; Grisendi, Giulia; Petrachi, Tiziana; Conte, Pierfranco; Horwitz, EDWIN MARK; Campana, Dario; Paolucci, Paolo; Dominici, Massimo
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. 1-gen-1993 S., Spagnesi; F., Ducci; M., Laddaga; A., Falcone; Conte, Pierfranco; A., Pandolfi; C. G., Stampino
A phase II study of mitoxantrone in advanced breast cancer. 1-gen-1986 P., Pronzato; A., Ardizzoni; Conte, Pierfranco; M., Gulisano; R., Lionetto; L., Repetto; V., Scornavacche; M. R., Sertoli; R., Rosso
A phase II study with danazol in metastatic breast cancer. 1-gen-1987 P., Pronzato; D., Amoroso; A., Ardizzoni; G., Bertelli; Conte, Pierfranco; A., Michelotti; R., Rosso
A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer. 1-gen-1996 C., Tibaldi; E., Baldini; S., Ricci; Conte, Pierfranco
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 1-gen-2008 Guarneri, Valentina; Piacentini, Federico; A., Frassoldati; G., Ficarra; D'Amico, Roberto; Giovannelli, Simona; Conte, Pierfranco